Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Ney
Alexander Ney, Le Puy Ste Reparade FR
| Patent application number | Description | Published |
|---|---|---|
| 20120099359 | Nonvolatile Memory Architecture - Representative implementations of memory devices have transistors between memory cells of a memory device. Memory devices may be arranged in memory arrays. The use of transistors may include alternately providing electrical isolation or current paths between pairs or groups of memory cells in a memory array. | 04-26-2012 |
David Ney, Chambery FR
| Patent application number | Description | Published |
|---|---|---|
| 20100301487 | IMPROVEMENTS IN OR RELATING TO INTEGRATED CIRCUIT RELIABILITY - A method of manufacturing an integrated circuit having minimized electromigration effect, wherein the integrated circuit comprises one or more interconnect, said the or each interconnect comprising a dielectric layer having an intrinsic parameter at a first defined value, characterized in that said method comprises: identifying one or more characteristics of the or each interconnect; determining a minimal process distance from the or each interconnect for the application of one or more first metal elements; calculating a required correction parameter which can correct the intrinsic parameter at said first defined value; calculating a required number of the first metal elements which have the intrinsic parameter at a second defined value, such that the second defined value provides the required correction parameter for the first defined value; applying a plurality of said first metal elements around the interconnect at said minimum process distance to overcome the problem of electromigration caused by the intrinsic parameter at the first defined value. | 12-02-2010 |
Denise M. Ney, Brooklyn, WI US
| Patent application number | Description | Published |
|---|---|---|
| 20100317597 | GLYCOMACROPEPTIDE MEDICAL FOODS FOR NUTRITIONAL MANAGEMENT OF PHENYLKETONURIA AND OTHER METABOLIC DISORDERS - Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria. | 12-16-2010 |
Gina Ney, Ann Arbor, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20100222400 | F1F0-ATPase Inhibitors and Related Methods - The present invention relates to a family of guanidine-based F1F0-ATPase inhibitors, e.g., mitochondrial F1F0-ATPase inhibitors, methods for their discovery, and their use as therapeutic agents for treating certain disorders. | 09-02-2010 |
| 20110251200 | ARYL GUANIDINE F1F0-ATPASE INHIBITORS AND RELATED METHODS - The invention provides to a family of aryl guanidine-based F | 10-13-2011 |
Hartmut Ney, Konstanz DE
| Patent application number | Description | Published |
|---|---|---|
| 20080226712 | Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles - The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions. | 09-18-2008 |
| 20090208571 | Dosage form containing pantoprazole as active ingredient - Dosage forms for the oral administration of the magnesium salt of pantoprazole are described. | 08-20-2009 |
| 20110060016 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient - Disclosed is a method of treatment of COPD by oral administration of roflumilast. | 03-10-2011 |
| 20110171303 | DOSAGE FORM CONTAINING (S)-PANTOPRAZOLE AS ACTIVE INGREDIENT - Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described. | 07-14-2011 |
| 20110251244 | Oral Dosage Form Containing A PDE 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidone As Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 10-13-2011 |
Jörg-Werner Ney, Schwalbach DE
| Patent application number | Description | Published |
|---|---|---|
| 20120004870 | METHOD AND DEVICE FOR MONITORING A PHOTOVOLTAIC UNIT - In a method and a device ( | 01-05-2012 |
Jörg-Werner Ney, Schwalbach DE
| Patent application number | Description | Published |
|---|---|---|
| 20120004870 | METHOD AND DEVICE FOR MONITORING A PHOTOVOLTAIC UNIT - In a method and a device ( | 01-05-2012 |
Paul Ney, Moreno Valley, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110182392 | STAGED Z-PINCH FOR THE PRODUCTION OF HIGH-FLUX NEUTRONS AND NET ENERGY - A fusible target is embedded in a high Z liner, ohmically heated and then shock wave heated by implosion of an enveloping high Z liner. The target is adiabatically heated by compression, fusibly ignited and charged-particle heated as it is being ignited. A shock front forms as the liner implodes which shock front detaches from the more slowly moving liner, collides with the outer surface of the target, accelerates inward, rapidly heating the target, adiabatically compressing the target and liner and amplifying the current to converge the liner mass toward a central axis thereby compressing the target to a fusion condition when it begins to ignite and produce charged particles. The charged particles are trapped in a large magnetic field surrounding the target. The energy of the charged particles is deposited into the target to further heat the target to produce an energy gain. | 07-28-2011 |
Peter Ney, Grevenbroich DE
| Patent application number | Description | Published |
|---|---|---|
| 20080249114 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS - This invention relates to novel aryloxypropanolamines. The invention also relates to the pharmaceutically acceptable salts and solvates containing said compounds, methods for the preparation thereof and to respective synthetic intermediates. Said compounds have agonistic activity at β3 adrenergic receptors and are useful for treatment of ailments influenced by activation of β3 adrenergic receptors. | 10-09-2008 |